{
    "clinical_study": {
        "@rank": "75571", 
        "acronym": "Anakinra ADHF", 
        "arm_group": [
            {
                "arm_group_label": "Anakinra (short)", 
                "arm_group_type": "Experimental", 
                "description": "Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo injections twice daily for the first 3 days then once daily for days 4-14."
            }
        ], 
        "brief_summary": {
            "textblock": "Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human\n      interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart\n      failure with the aim to quench the acute inflammatory response, as measured by the\n      area-under-the-curve for C reactive protein over 14 days."
        }, 
        "brief_title": "IL-1 Blockade in Acute Heart Failure", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All 5 criteria need to be met for enrollment of the patient in the study\n\n          1. Primary diagnosis of acute decompensated heart failure within the last 24 hours as\n             evidenced by BOTH of the following:\n\n               1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion\n\n               2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least\n                  one of the conditions must be met);\n\n             i. pulmonary congestion/edema at physical exam OR chest XRay; ii. plasma BNP levels\n             \u2265200 pg/mL; iii.invasive measurement of left ventricular end-diastolic pressure >18\n             mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.\n\n          2. Left ventricular systolic dysfunction (LVEF<40%) during index hospitalization or\n             prior 12 months.\n\n          3. Age \u226518 years old\n\n          4. Willing and able to provide written informed consent.\n\n          5. Screening plasma C-reactive protein levels >5 mg/L.\n\n        Exclusion Criteria Subjects will not be eligible if they meet any of the following 15\n        exclusion criteria.\n\n          1. The primary diagnosis for admission is NOT decompensated heart failure, including\n             diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or\n             brady-arrhythmias.\n\n          2. Concomitant clinically significant comorbidities that would interfere with the\n             execution or interpretation of the study including but not limited to acute coronary\n             syndromes, uncontrolled hypertention or orthostatic hypotension, tachy- or\n             brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders\n             affecting respiration.\n\n          3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT),\n             coronary artery revascularization procedures, or heart valve surgeries.\n\n          4. Previous or planned implantation of left ventricular assist devices or\n             heart-transplant.\n\n          5. Chronic use of intravenous inotropes.\n\n          6. Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including\n             NSAIDs).\n\n          7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis,\n             systemic lupus erythematosus).\n\n          8. Active infection (of any type);\n\n          9. Chronic/recurrent infectious disease (including HBV, HCV, and HIV/AIDS).\n\n         10. Prior (within the past 10 years) or current malignancy.\n\n         11. Any comorbidity limiting survival or ability to complete the study.\n\n         12. End stage kidney disease requiring renal replacement therapy.\n\n         13. Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).\n\n         14. Pregnancy.\n\n         15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion\n             during cardiopulmonary exercise testing obtained during the baseline testing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936844", 
            "org_study_id": "VCU HM15347"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anakinra (short)", 
                "description": "Anakinra 100 mg daily twice daily for days 1, 2 and 3", 
                "intervention_name": "Anakinra (high dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Anakinra (short)", 
                "description": "Anakinra 100 mg daily for days 4-14", 
                "intervention_name": "Anakinra (standard dose)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interleukin 1 Receptor Antagonist Protein"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "bvantassell@vcu.edu", 
                "last_name": "Benjamin W Van Tassell, PharmD", 
                "phone": "804-828-4583"
            }, 
            "contact_backup": {
                "email": "aabbate@vcu.edu", 
                "last_name": "Antonio Abbate, MD, PhD", 
                "phone": "804-828-0513"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23298"
                }, 
                "name": "Virginia Commonwealth University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interleukin-1 Blockade in Acute Decompensated Heart Failure", 
        "overall_contact": {
            "email": "bvantassell@vcu.edu", 
            "last_name": "Benjamin W Van Tassell, PharmD", 
            "phone": "804-8284583"
        }, 
        "overall_contact_backup": {
            "email": "aabbate@vcu.edu", 
            "last_name": "Antonio Abbate, MD, PhD", 
            "phone": "804-8280513"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Anakinra ADHF Data Safety and Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The area-under-the-curve for plasma C reactive protein (CRP) levels measured at admission and then on day 2, 3, 4, 5 and 14.", 
            "measure": "C reactive protein", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936844"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Placebo-corrected interval change in left ventricular ejection fraction (LVEF) between admission and 14 day follow up", 
                "measure": "Left ventricular ejection fraction", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Placebo-corrected interval changed in flow mediated vasodilatation of the brachial artery.", 
                "measure": "Brachial artery vasoreactivity", 
                "safety_issue": "No", 
                "time_frame": "3 days"
            }
        ], 
        "source": "Virginia Commonwealth University", 
        "sponsors": {
            "collaborator": {
                "agency": "American Heart Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}